Advanced Clinical & Regulatory
Mastery Test :Questions And
Answer With Rationales /Graded
A+ Update 100% Correct
SECTION I: CARDIOVASCULAR & RESPIRATORY UPDATES (Qs
1-15)
1. A 58-year-old male with a 20-pack-year history presents with dyspnea. Spirometry
shows FEV1/FVC 0.68. According to the 2026 GOLD guidelines, which
pharmacological agent is recommended as first-line for Group E patients (high
exacerbation risk)?
A) Short-acting beta-agonist (SABA) as needed
B) Low-dose theophylline
C) Triple therapy (LABA+LAMA+ICS) ✔️
D) Roflumilast monotherapy
Rationale: 2026 GOLD guidelines update: For Group E patients (≥2 moderate
exacerbations or ≥1 hospitalization), triple therapy (LABA/LAMA/ICS) is now first-line,
moving ICS earlier than prior guidelines.
2. A patient presents with acute onset of severe right leg pain and pallor. Point-of-
care ultrasound shows no flow in the popliteal artery. ECG shows new-onset atrial
fibrillation. Which intervention has the highest priority within 6 hours of symptom
onset?
A) Intravenous heparin bolus only
B) CT angiography of the lower extremity
C) Surgical thrombectomy or catheter-directed thrombolysis ✔️
D) Compression stockings and observation
Rationale: Acute limb ischemia (Rutherford IIa) requires revascularization within 6
hours to prevent amputation. Heparin is adjunctive, not definitive. Delaying for
imaging wastes critical time.
,3. Regarding the 2026 ACC/AHA hypertension guidelines, what is the new
recommended first-line therapy for non-diabetic Black patients with stage 2
hypertension (BP >140/90)?
A) ACE inhibitor monotherapy
B) Thiazide diuretic or CCB (amlodipine) ✔️
C) Direct renin inhibitor
D) Beta-blocker only
Rationale: Evidence continues to show ACE inhibitors have reduced efficacy as
monotherapy in Black patients due to lower renin levels. Thiazides or CCBs are
preferred initial agents.
4. A 72-year-old is prescribed apixaban for NVAF. She starts rifampin for latent TB.
What change is required per 2026 pharmacokinetic safety updates?
A) Double the dose of apixaban
B) Switch apixaban to once daily
C) Switch to warfarin or a different DOAC not metabolized by CYP3A4 ✔️
D) No change; no interaction exists
Rationale: Rifampin is a strong inducer of CYP3A4 and P-gp, dramatically reducing
apixaban levels. The 2026 FDA safety update mandates switching to a non-CYP3A4
dependent anticoagulant (warfarin) or dabigatran (less dependent).
5. Which echocardiographic finding is the strongest predictor of early mortality in
severe aortic stenosis according to the 2026 European Society of Cardiology update?
A) Aortic valve area 0.8 cm²
B) Mean gradient 45 mmHg
C) Global longitudinal strain (GLS) less than -15% ✔️
D) Left atrial volume index >34 mL/m²
Rationale: While all are abnormal, GLS reflects early subendocardial fibrosis. A GLS
worse than -15% indicates myocardial decompensation and predicts sudden death,
triggering earlier valve intervention.
6. For a patient with resistant hypertension on maximal doses of ACEi, ARB, CCB, and
thiazide, the 2026 guidelines suggest adding which agent next?
A) Spironolactone 25 mg
B) Finerenone (non-steroidal MRA) ✔️
C) Clonidine 0.1 mg TID
D) Hydralazine 50 mg QID
Rationale: The FIGARO-DKD 2026 update shows finerenone provides superior
cardiorenal protection with less hyperkalemia than spironolactone in resistant
hypertension with or without diabetes.
, 7. A patient using a SGLT2 inhibitor for heart failure develops euglycemic diabetic
ketoacidosis (euDKA). Which precipitant is most commonly identified in 2026
pharmacovigilance data?
A) High carbohydrate meal
B) Intermittent fasting or low-carbohydrate diet ✔️
C) Concurrent metformin use
D) Recent COVID-19 booster
Rationale: SGLT2i-induced euDKA is strongly linked to ketosis from low
carbohydrate intake/ketogenic diets. Fasting increases ketone production while
SGLT2i reduces insulin secretion.
8. What is the first-line vasopressor recommended for septic shock in the 2026
Surviving Sepsis Campaign update?
A) Dopamine
B) Epinephrine
C) Norepinephrine ✔️
D) Vasopressin
Rationale: Norepinephrine remains first-line. Vasopressin is added as second-line
(not monotherapy). Epinephrine is reserved for refractory shock.
9. A post-COVID patient has persistent resting tachycardia (110 bpm) without
orthostasis. Holter shows sinus tachycardia. 2026 consensus guidelines recommend
which initial treatment?
A) Ivabradine 5 mg BID
B) Supervised exercise training and beta-blockers (metoprolol) ✔️
C) Catheter ablation of sinus node
D) High-dose prednisone
Rationale: Post-COVID autonomic dysfunction (PASC-related) initially responds to
beta-blockers and graded exercise. Ivabradine is reserved for beta-blocker
intolerance (2026 AHA guidance).
10. In managing acute pulmonary embolism with RV dysfunction but stable BP, 2026
guidelines recommend which of the following as first-line?
A) Systemic thrombolysis (tPA)
B) ECMO cannulation
C) Therapeutic anticoagulation with monitoring for decompensation ✔️
D) Surgical embolectomy
Rationale: Submassive PE (hemodynamically stable with RV strain) is managed with
anticoagulation first. Thrombolytics are for hemodynamic instability (massive PE) or
clinical deterioration.
Mastery Test :Questions And
Answer With Rationales /Graded
A+ Update 100% Correct
SECTION I: CARDIOVASCULAR & RESPIRATORY UPDATES (Qs
1-15)
1. A 58-year-old male with a 20-pack-year history presents with dyspnea. Spirometry
shows FEV1/FVC 0.68. According to the 2026 GOLD guidelines, which
pharmacological agent is recommended as first-line for Group E patients (high
exacerbation risk)?
A) Short-acting beta-agonist (SABA) as needed
B) Low-dose theophylline
C) Triple therapy (LABA+LAMA+ICS) ✔️
D) Roflumilast monotherapy
Rationale: 2026 GOLD guidelines update: For Group E patients (≥2 moderate
exacerbations or ≥1 hospitalization), triple therapy (LABA/LAMA/ICS) is now first-line,
moving ICS earlier than prior guidelines.
2. A patient presents with acute onset of severe right leg pain and pallor. Point-of-
care ultrasound shows no flow in the popliteal artery. ECG shows new-onset atrial
fibrillation. Which intervention has the highest priority within 6 hours of symptom
onset?
A) Intravenous heparin bolus only
B) CT angiography of the lower extremity
C) Surgical thrombectomy or catheter-directed thrombolysis ✔️
D) Compression stockings and observation
Rationale: Acute limb ischemia (Rutherford IIa) requires revascularization within 6
hours to prevent amputation. Heparin is adjunctive, not definitive. Delaying for
imaging wastes critical time.
,3. Regarding the 2026 ACC/AHA hypertension guidelines, what is the new
recommended first-line therapy for non-diabetic Black patients with stage 2
hypertension (BP >140/90)?
A) ACE inhibitor monotherapy
B) Thiazide diuretic or CCB (amlodipine) ✔️
C) Direct renin inhibitor
D) Beta-blocker only
Rationale: Evidence continues to show ACE inhibitors have reduced efficacy as
monotherapy in Black patients due to lower renin levels. Thiazides or CCBs are
preferred initial agents.
4. A 72-year-old is prescribed apixaban for NVAF. She starts rifampin for latent TB.
What change is required per 2026 pharmacokinetic safety updates?
A) Double the dose of apixaban
B) Switch apixaban to once daily
C) Switch to warfarin or a different DOAC not metabolized by CYP3A4 ✔️
D) No change; no interaction exists
Rationale: Rifampin is a strong inducer of CYP3A4 and P-gp, dramatically reducing
apixaban levels. The 2026 FDA safety update mandates switching to a non-CYP3A4
dependent anticoagulant (warfarin) or dabigatran (less dependent).
5. Which echocardiographic finding is the strongest predictor of early mortality in
severe aortic stenosis according to the 2026 European Society of Cardiology update?
A) Aortic valve area 0.8 cm²
B) Mean gradient 45 mmHg
C) Global longitudinal strain (GLS) less than -15% ✔️
D) Left atrial volume index >34 mL/m²
Rationale: While all are abnormal, GLS reflects early subendocardial fibrosis. A GLS
worse than -15% indicates myocardial decompensation and predicts sudden death,
triggering earlier valve intervention.
6. For a patient with resistant hypertension on maximal doses of ACEi, ARB, CCB, and
thiazide, the 2026 guidelines suggest adding which agent next?
A) Spironolactone 25 mg
B) Finerenone (non-steroidal MRA) ✔️
C) Clonidine 0.1 mg TID
D) Hydralazine 50 mg QID
Rationale: The FIGARO-DKD 2026 update shows finerenone provides superior
cardiorenal protection with less hyperkalemia than spironolactone in resistant
hypertension with or without diabetes.
, 7. A patient using a SGLT2 inhibitor for heart failure develops euglycemic diabetic
ketoacidosis (euDKA). Which precipitant is most commonly identified in 2026
pharmacovigilance data?
A) High carbohydrate meal
B) Intermittent fasting or low-carbohydrate diet ✔️
C) Concurrent metformin use
D) Recent COVID-19 booster
Rationale: SGLT2i-induced euDKA is strongly linked to ketosis from low
carbohydrate intake/ketogenic diets. Fasting increases ketone production while
SGLT2i reduces insulin secretion.
8. What is the first-line vasopressor recommended for septic shock in the 2026
Surviving Sepsis Campaign update?
A) Dopamine
B) Epinephrine
C) Norepinephrine ✔️
D) Vasopressin
Rationale: Norepinephrine remains first-line. Vasopressin is added as second-line
(not monotherapy). Epinephrine is reserved for refractory shock.
9. A post-COVID patient has persistent resting tachycardia (110 bpm) without
orthostasis. Holter shows sinus tachycardia. 2026 consensus guidelines recommend
which initial treatment?
A) Ivabradine 5 mg BID
B) Supervised exercise training and beta-blockers (metoprolol) ✔️
C) Catheter ablation of sinus node
D) High-dose prednisone
Rationale: Post-COVID autonomic dysfunction (PASC-related) initially responds to
beta-blockers and graded exercise. Ivabradine is reserved for beta-blocker
intolerance (2026 AHA guidance).
10. In managing acute pulmonary embolism with RV dysfunction but stable BP, 2026
guidelines recommend which of the following as first-line?
A) Systemic thrombolysis (tPA)
B) ECMO cannulation
C) Therapeutic anticoagulation with monitoring for decompensation ✔️
D) Surgical embolectomy
Rationale: Submassive PE (hemodynamically stable with RV strain) is managed with
anticoagulation first. Thrombolytics are for hemodynamic instability (massive PE) or
clinical deterioration.
